Modulation of sirtuins: New targets for antiageing

Recent Patents on CNS Drug Discovery

Volumn 3, Issue 1, 2008, Pages 61-69

  Pallàs, Mercè ^a,b   Verdaguer, Esther ^a   Tajes, Marta ^a   Gutierrez Cuesta, Javier ^a   Camins, Antoni ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Ageing; Deacetylases; Neurodegenerative diseases; Polyphenols

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BENZIMIDAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CATALASE; GLUTAMATE DEHYDROGENASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NICOTINAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHENOL DERIVATIVE; PROTEIN KINASE B; PROTEIN P53; PYRIDINE DERIVATIVE; QUERCETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RESVERATROL; SILENT INFORMATION REGULATOR PROTEIN; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTINOL; SIRTINOL DERIVATIVE; SIRTUIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CALORIC RESTRICTION; CELL DEATH; DNA DAMAGE; DNA RECOMBINATION; DNA REPAIR; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION;

AGING; ANIMALS; DEMENTIA; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES; SIRTUINS; STILBENES;

EID: 38949185264     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488908783421492     Document Type: Review

References (117)

1. Trollor JN, Valenzuela MJ. Brain ageing in the new millennium. Aust. N. Z. J Psychiatry 2001; 35: 788-805.
2. Esiri MM. Ageing and the brain. J Pathol 2007; 211: 181-187.
3. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Atzheimer's disease. Lancet 2004; 363: 392-394.
4. Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 2003; 23: 3295-3301.
5. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156:445-453.
6. Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell 695-110.
7. Dillin A, Crawford DK, Kenyon C. Timing requirements for insulin/IGF-1 signaling in C. elegans. Science 2002; 298: 830-834.
8. Hekimi S, Guarente L. Genetics and the specificity of the aging process. Science 2003; 299: 1351-1354.
9. Tatar M. Unearthing Loci that influence life span. Sci. Aging Knowledge. Environ 2003; E5.
10. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell 2005; 120: 449-460.
11. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495.
12. Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006; 96:305-313.
13. Parker JA, Arango M, Abderrahmane S, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005b; 37: 349-350.
14. Sakamoto J, Miura T, Shimamoto K, Horio Y. Predominant expression of Sir2[alpha], an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Letters 2004; 556: 281-286.
15. Trapp J, Jung M. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr. Drug Targets 2006; 7: 1553-1560.
16. Munch G, Kuhla B, Luth HJ, Arendt T, Robinson SR. Anti-Ageing defences against Alzheimer's disease. Biochem Soc Trans 2003; 31: 1397-1399.
17. Mattson MP. Dietary factors, hormesis and health. Ageing Res Rev 2007. doi:10.1016/j.arr.2007.08.005
18. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tauprotein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 1993; 336: 417-424.
19. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13: 2570-2580.
20. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001; 410: 227-230.
21. Sinclair D. Sirtuins for healthy neurons. Nat Genet 2005; 37: 339-340.
22. Grubisha O, Smith BC, Denu JM. Small molecule regulation of Sir2 protein deacetylases. FEBS J 2005; 272: 4607-4616.
23. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999; 260: 273-279.
24. Frye R A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000; 273: 793-798.
25. Tang BL, Chua CE. SIRT1 and neuronal diseases. Mol Aspects Med 2007.
26. Tang BL. SIRT1, neuronal cell survival and the insulin/IGF-1 aging paradox. Neurobiology of Aging 2006; 27: 501-505.
27. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 2004; 306: 2105-2108.
28. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-392.
29. Lin SJ, Kaeberlein M, Andalis AA, et al. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature 2002; 418: 344-348
30. Lin SJ, Ford E, Haigis M, Liszt G, Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 2004; 18: 12-16.
31. Lin SS, Manchester JK, Gordon JI. Enhanced Gluconeogenesis and Increased Energy Storage as Hallmarks of Aging in Saccharomyces cerevisiae. J Biol Chem 2001; 276: 36000-36007.
32. Martin B, Mattson MP, Maudsley S. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev 2006; 5: 332-353.
33. Fructus, A.: WO07104867 (2007).
34. Inoue T, Hiratsuka. M, Osaki M, Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6: 1011-1018.
35. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305: 1010-1013.
36. Defossez PA, Lin SJ, McNabb DS. Sound silencing: the Sir2 protein and cellular senescence. Bioessays 2001; 23: 327-332.
37. Chua KF, Mostoslavsky R, Lombard DB, et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2005; 2:67-76.
38. Wong S, Weber JD. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J 2007; 407: 451-460.
39. Furukawa A, Tada-Oikawa S, Kawanishi S, Oikawa S. H2O2 accelerates cellular senescence by accumulation of acetylated p53 via decrease in the function of SIRT1 by NAD+ depletion. Cell Physiol Biochem 2007; 20: 45-54.
40. Kobayashi Y, Furukawa-Hibi Y, Chen C, et al. SIRT1 is critical regulator of FoxO-mediated transcription in response to oxidative stress. Int J Mol Med 2005; 16: 237-243.
41. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-4635.
42. Denu JM. The Sir 2 family of protein deacetylases. Curr Opin Chem Biol 2005; 9: 431-440.
43. Guarente, L.P., Haigis, M.C.: US20070099830 (2007).
44. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-1234.
45. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1 {alpha}. J Biol Chem 2005; 280: 16456-16460.
46. li-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med 2007; 39: 335-345.
47. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006; 127: 1109-1122.
48. Kaestner KH. The hepatocyte nuclear factor 3 (HNF3 or FoxA) family in metabolism. Trends Endocrinol Metab 2000; 11: 281-285.
49. Yeagley D, Guo S, Unterman T, Quinn PG. Gene- and activation-specific mechanisms for insulin inhibition of basal and glucocorticoid-induced insulin-like growth factor binding protein-1 and phosphoenolpyruvate carboxykinase transcription. Roles of forkhead and insulin response sequences. J Biol Chem 2001; 276: 33705-33710.
50. Nakae J, Kitamura T, Ogawa W, Kasuga M, Accili D. Insulin regulation of gene expression through the forkhead transcription factor Foxo1 (Fkhr) requires kinases distinct from Akt. Biochemistry 2001; 40: 11768-11776.
51. Tran H, Brunet A, Grenier JM, et al. DNA repair pathway stimulated by the forkhead transcription factor FoxO3a through the GADD45 protein. Science 2002; 296: 530-534.
52. Kops GJ, Dansen TB, Polderman PE, et al. Forkhead transcription factor FoxO3a protects quiescent cells from oxidative stress. Nature 2002; 419: 316-321.
53. Wang F. Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FoxO3a in response to oxidative stress and caloric restriction. Aging Cell 2007; 6: 505-514.
54. van der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004; 380: 297-309.
55. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002; 27: 352-360.
56. Schmidt M, Fernandez de MS, van der HA, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002; 22: 7842-7852.
57. Rathbone CR, Booth FW, Lees SJ. FoxO3a preferentially induces p27(Kip1) expression while impairing muscle precursor cell-cycle progression. Muscle Nerve 2007; 37: 84-89
58. Brunet A, Sweeney LB, Sturgill IF. Stress-dependent regulation of FoxO transcription factors by the SIRT1 deacetylase. Science 2004a; 303: 2011-2015.
59. Vaziri H, Dessain SK, Ng EE, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107: 149-159.
60. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148.
61. van der Heide LP, Smidt MP. Regulation of FoxO activity by CBP/ p300-mediated acetylation. Trends Biochem Sci 2005; 30: 81-86.
62. You H, Mak T W. Crosstalk between p53 and FoxO transcription factors Cell Cycle 2005; 4: 37-38.
63. Oh SW, Mukhopadhyay A, Svrzikapa N, Jiang F, Davis RJ, Tissenbaum HA. JNK regulates lifespan in Caenorhabditis elegans by modulating nuclear translocation of forkhead transcription factor/DAF-16. Proc Natl Acad Sci USA 2005; 102: 4494-4499.
64. Wang J, Zhai Q, Chen Y, et al. A local mecharism mediates NAD-dependent protection of axon degeneration. J Cell Bioi 2005; 170: 349-355.
65. Qin W, Yang T, Ho L, et al. Neuronal SIRT1 Activation as a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction. J Biol Chem 2006; 281: 21745-21754.
66. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317: 516-519.
67. Ghosh S, Feany MB. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum Mol Genet 2004; 13: 2011-2018.
68. Sinclair, D.A., Mai, A.: WO07084162 (2007).
69. Boris MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratiol. J Biol Chem 2005. 280: 17187-17195.
70. Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-spocific activation of sirtuins by resveratrol. J Biol Chem 2005; 280: 17038-17045.
71. Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 290: 40364-40374.
72. Mai A, Massa S, Lavu S, Pezzi R, et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem 2005; 48: 7789-7795.
73. Tamburini BA, Tyler JK. Localized histone acetylation and deacetylation triggered by the homologous recombination pathway of double-strand DNA repair. Mol Cell Biol 2005; 25: 4903-4913.
74. Kruszewski K Szumiel I. Sirtuins (histone deacetylases III) in the cellular response to DNA damage-facts and hypotheses. DNA Repair (Amst) 2005; 4: 1306-1313.
75. Barthelemy C, Henderson CE, Pettmann B. Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK. BMC Neurosci. 2004; 5: 48.
76. Stahl M, Dijkers PF, Kops GJ, et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in resporse to IL-2. J Immunol 2002; 168: 5024-5031.
77. Nunes, J.J., Milne, J., Bemis, J., Xie, R., Vu, C.B., Ng, P.Y., Disch, J.S.: US20070043050 (2007).
78. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007; 28: 277-290.
79. Smith J. Human Sir2 and the'silencing' of p53 activity. Trends Cell Biol 2002; 12: 404-406.
80. Tervo AJ, Suuronen T, Kyrylenko S, et al. Discovering inhibitors of human sirtuin type 2: novel structural scaffolds. J Med Chem 2006; 49: 7239-7241.
81. Droge W, Schipper HM. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 2007; 6: 361-370.
82. Wei YH, Lee HC. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp Biol Med (Maywood) 2002; 227: 671-682.
83. Atlante A, Bobba A, Calissano, P, Passarella S, Marra E. The apoptosis/ necrosis transition in cerebellar granule cells depends on the mutual relationship of the antioxidant and the proteolytic systems which regulate ROS production and cytochrome c release en route to death. J Neurochem 2003; 84:960-971.
84. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002, 84: 131-141.
85. Fujimura M, Morita-Fujimura Y, Noshita N, Sugawara T, Kawase M, Chan PH. The cytosolic antioxidant copper/zinc-superoxide dismutase prevents the early release of mitochondrial cytochrome c in ischemic brain after transient focal cerebral ischemia in mice. J Neurosci 2000; 20: 2817-2824.
86. Nakagawa T, Ito T, Fujimura S, et al. Molecular characterization of the glutathione-dependent formaldehyde dehydrogenase gene FLD1 from the mathylotrophic yeast Pichra methanolica. Yeast 2004; 21: 445-453.
87. Losa GA. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Invest 2003; 33: 818-823.
88. Wu A, Ying Z, Gomez-Pinilla F. Oxidative stress modulates Sir2alpha in rat hippocampus and cerebral cortex. Eur J Neurosci 2006; 23: 2573-2580.
89. Jang JH, Surh YJ. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 2003; 34: 1100-1110.
90. Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002; 71: 2489-2499.
91. Lefevre J, Michaud SE, Haddad P, et al. Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: Effect on endothelial progenitor cells and nitric oxide. FASEB J 2007; 21:3845-3907.
92. Wang J, Ho L, Zhao Z, et al. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease, FASEB J 2006b; 20:2313-2320.
93. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 2004; 141: 997-1005.
94. Savaskan E, Olivien G, Meier F, Seifritz E, Wirz-Justice A, Muller-Spahn F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 2003; 49: 380-383.
95. Bastianetto S, Brouillette J, Quirion R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem Res. 2007; 32: 1720-1725.
96. Bastianetto S, Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol Aging 2002; 23:891-897.
97. Wang J, Ho L, Zhao Z, et al. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 2006a; 20: 2313-2320.
98. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652-1658.
99. Carluccio MA, Ancora MA, Massaro M, et al. Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. Am J Physiol Heart Circ Physiol 2007; 293: H2344-H2354.
100. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280: 37377-37382.
101. Alvira D, Yeste-Velasco M, Folch J, et al. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex 1 and potassium deprivation in cerebellar neurons. Neuroscience 2007; 147:746-756.
102. Zhuang H, Kim YS, Koehler RC, Dore S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons Ann NY Acad Sci 2003; 993: 276-286.
103. Han YS, Bastianetto S, Dumont Y, Quirion R. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther 2006; 318: 238-245.
104. Stefani M, Markus MA, Lin RC, Pinese M, Dawes IA, Morris BJ. The Effect of Resveratrol on a Cell Model of Human Aging. Ann NY Acad Sci 2007.
105. Kops GJ, Medema RH, Glassford J, et al. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002; 22: 2025-2036.
106. Ghosh HS, Spencer JV, Ng B, McBurney MW, Robbins PD. Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor kappaB-mediated transcription. Biochem J 2007; 408: 105-111.
107. Daitoku H, Hatta IA, Matsuzaki H, et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci USA 2004; 101: 10042-10047.
108. Orallo F. Comparative studies of the antioxidant effects of cis- and. trans-resveratrol. Curr Med Chem 2006; 13: 87-98.
109. Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663-673.
110. Aumont V, Krisa S, Battaglia E, et al. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch. Biochem Biopbys 2001; 393:281-289.
111. Nunes, J.J., Milno, J., Bemis, J., Xie, R., Vu, B., Ng, P.Y., Disco, J. S.: US20070037865A1 (2007)
112. Nunes, J.J., Milne, J., Bernis, J., Xie, R., Vu, B., Ng, P.Y., Disco, J. S.: US20070037827 (2007).
113. Nunes, J.J., Milne, J., Bemis, J., Xie, R., Vu, B., Ng, P.Y., Disco, J. S., Salmann T., Armistead, D.: WO07019346 (2007).
114. Nunes, J.J., Milne, J., Bemis, J., Xie, R., Vu, B., Ng, P.Y., Disco, J. S., Salmann T., Armistead, D: US20070037910 (2007).
115. Napper AD, Hixon J, McDonagh T, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005;48:8045-54.
116. Kiviranta PH, Leppanen J, Kyrylenko, et al. NW-Bisbenzyli-denebenzene-1,4-diamines and N,N'-Bisberzylidenenaphthatalene-1,4-diamines as Sirtuin Type 2 (SIRT2) inhibitors. J Med Chem 2006; 49: 7907-7911.
117. Nunes, J.J., Milne, J., Bemis, J., Xie, R., Vu, B., Ng, P.Y., Disco, J. S., Salmann, T., Armistead, D.: US20070037809 (2007).